Abstract:Regulated cell death (RCD) is a controlled form of cell death orchestrated by one or more cascading signaling pathways, making it amenable to pharmacological intervention. RCD subroutines can be categorized as apoptotic or non-apoptotic and play essential roles in maintaining homeostasis, facilitating development, and modulating immunity. Accumulating evidence has recently revealed that RCD evasion is frequently the primary cause of tumor survival. Several non-apoptotic RCD subroutines have garnered attention as promising cancer therapies due to their ability to induce tumor regression and prevent relapse, comparable to apoptosis. Moreover, they offer potential solutions for overcoming the acquired resistance of tumors toward apoptotic drugs. With an increasing understanding of the underlying mechanisms governing these non-apoptotic RCD subroutines, a growing number of small-molecule compounds targeting single or multiple pathways have been discovered, providing novel strategies for current cancer therapy. In this review, we comprehensively summarized the current regulatory mechanisms of the emerging non-apoptotic RCD subroutines, mainly including autophagy-dependent cell death, ferroptosis, cuproptosis, disulfidptosis, necroptosis, pyroptosis, alkaliptosis, oxeiptosis, parthanatos, mitochondrial permeability transition (MPT)-driven necrosis, entotic cell death, NETotic cell death, lysosome-dependent cell death, and immunogenic cell death (ICD). Furthermore, we focused on discussing the pharmacological regulatory mechanisms of related small-molecule compounds. In brief, these insightful findings may provide valuable guidance for investigating individual or collaborative targeting approaches towards different RCD subroutines, ultimately driving the discovery of novel small-molecule compounds that target RCD and significantly enhance future cancer therapeutics.

Targeted therapy for non‐small‐cell lung cancer: New insights into regulated cell death combined with immunotherapy

Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials

Recent progress in targeted therapy for non-small cell lung cancer

Targeted Therapy for Non-Small-cell Lung Cancer Using EGFR-TKIs

Therapeutic strategies of targeting non-apoptotic regulated cell death (RCD) with small-molecule compounds in cancer

Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy

Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives

Application of Immune Checkpoint Inhibitors in EGFR-mutant Non-Small-cell Lung Cancer: from Bed to Bench

Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer

Advances of Autophagy and EGFR-TKI Drug Resistance in the Treatment of Non-Small Cell Lung Cancer

Targeting regulated cell death in tumor nanomedicines

Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives

The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

Targeted regulated cell death with small molecule compounds in colorectal cancer: Current perspectives of targeted therapy and molecular mechanisms

Breakthrough in targeted therapy for non-small cell lung cancer

Current status of immunotherapy for non-small cell lung cancer

A pharmacological exploration of targeted drug therapy in non-small cell lung cancer

Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies

Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives

Advances of clinically approved small-molecule drugs for the treatment of non-small cell lung cancer

Targeted therapy in advanced non-small cell lung cancer: current advances and future trends